Companies
WeGene
a leading Chinese consumer-genomics brand (listed among the 2026 top-10 DTC brands alongside 23Mofang and MeGene), integrating DNA reports into WeChat lifestyle apps for diet and fitness recommendations.
- Country
- China
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total funding of $6.785847 million across three rounds (Angel, Series A, Series B) (2026-09-02) | caplight.com |
| Capacity | Annual testing capacity exceeds 1 million samples (2026-09-02) | mirror.wegene.com |
| Production site | Laboratories in Shenzhen (Futian and Pingshan districts) and Hong Kong (Tsim Sha Tsui) (2026-09-02) | 36kr.com · mirror.wegene.com · wegene.com |
| Headcount | 36 employees (as of 2025 annual report) (2025-12-31) | qiye.qizhidao.com |
| Certification | National High-tech Enterprise certification (obtained 2017) (2026-09-02) | mirror.wegene.com |
| Regulatory approval | In communication with NMPA and FDA for clinical diagnostic IVD products (2026-09-02) | 36kr.com |
Independent sources: 36kr.com · caplight.com · qiye.qizhidao.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| DTC genetic testing | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.